NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of NOX A12 in combination
with a background therapy of bendamustine and rituximab (BR) chemotherapy in previously
treated patients with chronic lymphocytic leukemia (CLL).